Voluntis (Paris:VTX) (Euronext Paris:VTX)(Mnemo:VTX) (ISIN:FR0004183960) on Wednesday announced its plans to enhance patient care coordination in immunology via innovative digital therapeutic software in collaboration with the research-based global biopharmaceutical company AbbVie.
Under the partnership, AbbVie will leverage Voluntis' proven Theraxium technology to make this new solution available to patients and providers in the US.
Through the Theraxium technology platform, Voluntis designs and operates multiple digital therapeutics, including Insulia and Diabeo in diabetes as well as eCO and ZEMY in oncology.
Based out of Boston and Paris, France, Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self-manage ther treatment every day, thus improving real-world outcomes and is a founding member of the Digital Therapeutics Alliance.
Samsung Bioepis launches OPUVIZ across Europe for ophthalmic conditions
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Bayer's KERENDIA receives FDA priority review for type 1 diabetes and kidney disease treatment
Dexcom launches Dexcom Flex CGM system for Type 2 diabetes patients in Germany
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Bayer to acquire Perfuse Therapeutics in USD2.45bn deal to expand ophthalmology pipeline
ZYUS Life Sciences receives second US pain management patent
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cirius Therapeutics introduces gestational diabetes initiative
Boehringer Ingelheim's survodutide phase 3 data show significant weight loss in obesity trial
AOTI reports strong real-world outcomes for TWO2 wound therapy
Ascletis completes enrolment for US Phase II study of ASC30 in diabetes
Renalytix advances kidneyintelX.Dkd scale-up with laboratory expansion and CE submission
FDA expands approval of Sanofi's Tzield for early-stage type 1 diabetes in young children